ArticleScientific reports2025
The regulatory effect of CoL10A1 to the intracranial vascular invasion and cell proliferation in breast cancer via EMT pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- COL10A1 overexpression potentially contributes to poor outcomes in breast cancer via autophagy and vasculogenic mimicry.Translational cancer research · 2026Article
- Overexpression of COL10A1 in extracellular matrix predicts poor outcome and promotes ovarian cancer progression.BMC cancer · 2026Article
- COL10A1 beyond skeletal development: a hypertrophic chondrocyte-specific collagen emerging as a potential biomarker and tumor microenvironment regulator in solid cancers.American journal of cancer research · 2026Review
- Collagen dynamics in the breast cancer tumor microenvironment and therapeutic perspectives.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advances in breast cancer (BC) treatment technology, although it could prolong the BC patients' survival, brain metastasis (BM) is increasing gradually. Patients with brain metastasis of breast cancer (BMBC) could have the decline of survival rate and quality of life. Investigate the regulatory role of Collagen Type X Alpha 1 Chain (CoL10A1) in BMBC process was the aim of this study. CoL10A1 expression was analyzed from TCGA database and clinical tissues, and then detected the regulation of CoL10A1 on BC cells proliferation, migration, and invasion in BC cell lines and mouse models. Our findings indicated that BMBC tissues have significant levels of CoL10A1 expression. BC cells proliferation, migration and invasion may be inhibited by knocking down Co10A1 in vitro and in vivo. In addition, we found that knocking down CoL10A1 could reduce the penetration of 468 cells into hCMEC/D3 cells. Knocking down CoL10A1 regulated the epithelial-mesenchymal transition (EMT) pathway related proteins expression. CoL10A1 could regulate BC cells proliferation, migration and invasion, affect the penetration into hCMEC/D3 cells in vitro, and inhibit the intracranial vascular invasion in mouse models. These results suggested that CoL10A1 may be a new target for treating human BMBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.